I commented in response to your question yesterday (for the third time), but I am not sure why my posts were deleted just as soon as I posted them. Maybe it was because I included a link to the pomalidomide trial. In any event, bearofbleecker is on target with his analysis. In any event, I started a new thread to answer it.
In the long run pomalidomide shouldn't have an effect on Kyprolis sales for reason Bleecker posted. I will point out that pomalidomide is going for MM patients refractory to multiple treatment regimens including Velcade, so there could be some chance of it taking sales from Kyprolis in this population. However, Kyprolis will have a 6 months or more head start, and patients benefiting from it won't switch, and doctors using it will be more likely to use it for their other patients. In the long run, Kyprolis will be going after Velcade in front-line patients. Given its superior side-effect profile, I am guessing there could also be significant off-label usage of Kyprolis in this patient population. We will see in the next few quarters how it plays out, but I am not too concerned. Having said that, I am still looking to lighten up on ONXX a it to bank some profits as its big rise has made it too high of a percentage of my biotech portfolio for me to feel comfortable.